hrp0082p3-d2-823 | Growth (1) | ESPE2014

Correlation Between Initial Treatment Effect of Recombinant Human GH and Exon 3 Polymorphism of GH Receptor in Chinese GH Deficiency Children

Zheng Zhangqian , Cao Linfeng , Pei Zhou , Luo Feihong , Zhi Dijing , Zhao Zhuhui , Ye Rong , Cheng Ruoqian , Li Xiaojing

Objective and hypotheses: To investigate the frequency distribution of exon 3 deleted (d3-GHR) genetic polymorphism of GH receptor (GHR) in GH deficient (GHD) Chinese children and to explore the correlation between the growth promoting effects of recombinant human GH (rhGH) and exon 3 genetic polymorphism of GHR in GHD children.Method: 111 GHD (excluded small for gestational age) children were treated with rhGH (0.20 mg/kg per week) for 6 months. The bod...

hrp0084fc3.1 | Diabetes | ESPE2015

RNA-Based MAFA Over-Expression is Sufficient to Drive Human Pancreatic Duct-Derived Cells Toward a β-Cell-Like Phenotype

Corritore Elisa , Dugnani Erica , Pasquale Valentina , Piemonti Lorenzo , Vetere Amedeo , Bonner-Weir Susan , Sokal Etienne M , Lysy Philippe A

Background: Pancreatic epithelial cells represent an attractive cell source for replacement therapy of type 1 diabetes. Previously, we designed a protocol for expansion of human pancreatic duct-derived cells (HDDCs) and showed their β-cell engineering potential.Objective and hypotheses: In this study, we reprogrammed HDDCs into β-cell-like lineage by over-expressing mRNAs of key pancreatic transcription factors (TFs).Meth...

hrp0084p2-407 | GH & IGF | ESPE2015

A Phase 2, 6-Month, Randomised, Active-Controlled, Safety and Efficacy Study of TransCon hGH Compared to Daily Human GH in Children with GH Deficiency

Chatelain Pierre , Malievsky Oleg , Radziuk Klaudziya , Senatorova Ganna , Beckert Michael

Background: TransCon human GH (hGH) is a long-acting prodrug of recombinant hGH that releases fully active unmodified hGH. TransCon hGH was shown in phase 1 studies in healthy volunteers and a phase 2 study in adults with hGH deficiency to: i) be safe and well tolerated, ii) provide dose-dependent hGH levels, with same peak level and exposure compared to daily GH, iii) be suitable for a once-weekly dosing regimen, and iv) induce an IGF1 response within the normal range. This o...

hrp0097p1-132 | Growth and Syndromes | ESPE2023

One-year growth response and cost-effectiveness to Human recombinant growth hormone in girls with Turner Syndrome: Results from a large Egyptian retrospective study

Ibrahim Amany , Atef Abeer , Badawi Nora , Yassin Sahar , Helmy Eatemad

FDA licensed the use of human recombinant growth hormone (hGH) in girls with Turner Syndrome (TS) in 1997 as short stature is a consistent feature of this syndrome.Objective: we aimed to assess our 1-year experience of treating short girls with TS, to calculate their growth velocity, to analyze the patients’ characteristics and to investigate the possible factors that might affect their height gain.Me...

hrp0095p1-203 | Adrenals and HPA Axis | ESPE2022

P450 oxireductase (POR) regulates blood brain (BBB) maturation by mediating retinoic acid (RA) metabolism in a model of the human BBB

Dor Zlotnik , Tatiana Rabinski , Aviv Halfon , Inbar Plascheks , Hadar Benyamini , Yuval Nevo , Orly Yahalom-Gershoni , Benyamin Rosental , Ayal Ben-Zvi , Gad Vatine , Eli Hershkovitz

Background: The blood-brain barrier (BBB) is a multicellular neurovascular unit (NVU) that allows selective passage of necessary molecules into the central nervous system (CNS) while limiting the entry of neurotoxins and most drugs. A cross talk with pericytes and neural cells mediates the acquisition of tight junctions (TJs) in brain microvascular endothelial cells (BMECs), which limit the paracellular passage of solutes, thereby regulating CNS homeostasis. H...

hrp0095p1-179 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Loss of function of FIGNL1, a DNA damage response gene, is a novel cause of human ovarian dysgenesis

Florsheim Natan , Naugolny Larisa , Renbaum Paul , Lobel Orit , Y. Gold Merav , Goldberg Michal , Levy-Lahad Ephrat , Zangen David

Background: Severe Ovarian Dysgenesis (OD), a rare heterogeneous XX disorder of Sex Development presents clinically with primary amenorrhea, hypergonadotrophic hypogonadism and infertility. The genetic basis of OD remains unknown in 70% of cases. To identify novel causes of OD, we study patients in which known genes have been excluded.Methods: Whole-exome-sequencing was performed in a 14.5y old Ashkenazi Jewish, non-cons...

hrp0084fc9.2 | Beta cell disorders | ESPE2015

A Novel Source of Mesenchymal Stem Cells Lines from the Human Neonatal Pancreas of Patients with Congenital Hyperinsulinism in Infancy

Kellaway Sophie , Mosinska Karolina , Han Bing , Mohammad Zainab , Rigby Lindsey , Skae Mars , Padidela Raja , Banerjee Indi , Cosgrove Karen , Dunne Mark

Background: Congenital hyperinsulinism in infancy (CHI) is a neonatal disorder of uncontrolled insulin release leading to profound hypoglycaemia. In addition to defects in pancreatic β-cell function, we have recently demonstrated that the CHI pancreas is highly proliferative, with rates of proliferation up to 14-fold higher than in age-matched controls.Objective and hypotheses: As patients require pancreatectomy to alleviate hypoglycaemia, our aim w...

hrp0092p2-219 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Aromatase Inhibitor Treatment in Patient with Beta-Human Chorionic Gonadotrophin Secreting Tumor and Gonadotropin-Independent Precocious Puberty

Kiiaev Aleksei , Mazerkina Nadia , Astashova Ekaterina

Introduction: CNS tumors may cause precocious puberty (PP): in most cases gonadotropin-dependent PP, but in boys ß-HCG- secreting tumors may cause gonadotropin-independent (GIPP) with extremely high testosterone secretion due to Leidig cell stimulation by ß-HCG. Rapid bone maturation in such cases can lead to growth plate closure and poor final height prognosis. Aromatase inhibitor (AI) are administered in children with McCune-Olbright disease, famil...

hrp0095p1-499 | GH and IGFs | ESPE2022

Long-term safety and effectiveness of recombinant human growth Hormone inKorean pediatric patients with growth disorders: 9-year interim analysis fromLG Growth Study

Kim Yoo-Mi , Chung Sochung , Rhie Young-Jun , Hyun Kim Jae , Chae Hyun-Wook , Ho Choi Jin , Ah Lee Young , Sang Lee Hae , Tae Hwang Il

This study aimed to evaluate the long-term safety and effectiveness of recombinant human growth hormone (rhGH; Eutropin®, Eutropin®Pen, Eutropin®AQ, and Eutropin®Plus, LG Chem, Ltd.) treatment in Korean pediatric patients. This observational study has been conducted since 2011, and the data were collected up to August 2021 for interim analysis. The incidence rates of all adverse events (AEs) were assessed for safety a...

hrp0092p1-387 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Omnitrope® (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age (SGA): A Long-Term, Phase IV Study

Walczak Mieczyslaw , Giemza Tomasz , Jathanakodi Shrihari , Zouater Hichem , Zabransky Markus

Background: Short children born SGA are predisposed to metabolic abnormalities. While the benefit of recombinant human growth hormone in improving height is widely recognised, it can affect carbohydrate metabolism and lead to impaired glucose tolerance during treatment. This ongoing, prospective study is assessing the long-term safety and efficacy of Omnitrope® (somatropin) in children born SGA. Here we present data from an interim analysis con...